JP3917863B2 - Ｐｄｅ４アイソザイムの選択的阻害薬として有用なニコチンアミドベンゾ縮合複素環誘導体 - Google Patents

Ｐｄｅ４アイソザイムの選択的阻害薬として有用なニコチンアミドベンゾ縮合複素環誘導体 Download PDF

Info

Publication number: JP3917863B2
Authority: JP; Japan
Prior art keywords: formula; methyl; nicotinamide; benzo; oxy
Prior art date: 2000-01-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP2001557868A

Other languages

English (en)

Japanese (ja)

Other versions

JP2003522176A (ja

Inventor

マーファット，アンソニー

チャンバー，ロバート・ジェームズ

Original Assignee

ファイザー・プロダクツ・インク

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-31

Filing date

2001-01-30

Publication date

2007-05-23

2001-01-30 Application filed by ファイザー・プロダクツ・インク filed Critical ファイザー・プロダクツ・インク

2003-07-22 Publication of JP2003522176A publication Critical patent/JP2003522176A/ja

2007-05-23 Application granted granted Critical

2007-05-23 Publication of JP3917863B2 publication Critical patent/JP3917863B2/ja

2021-01-30 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

YLVAGBJBSYSJJJ-UHFFFAOYSA-N CC(C(C(c(cc1)ccc1SC)=O)N1)NC1=O Chemical compound CC(C(C(c(cc1)ccc1SC)=O)N1)NC1=O YLVAGBJBSYSJJJ-UHFFFAOYSA-N 0.000 description 1
GRNSAEXUTAGBSL-UHFFFAOYSA-N CC(C)(c1ccc(CN(CC=C)CC=C)cc1)O Chemical compound CC(C)(c1ccc(CN(CC=C)CC=C)cc1)O GRNSAEXUTAGBSL-UHFFFAOYSA-N 0.000 description 1
NDHOQAPKKVXVEH-UHFFFAOYSA-N CC(C)C(C(C)C)C(c(cc1OC)ccc1OCCCCCOc(cc1)ccc1C(N)=N)=O Chemical compound CC(C)C(C(C)C)C(c(cc1OC)ccc1OCCCCCOc(cc1)ccc1C(N)=N)=O NDHOQAPKKVXVEH-UHFFFAOYSA-N 0.000 description 1
NPFVRBCDMFKOPY-UHFFFAOYSA-N CC(C1)C(c2cc(-[n]3cncc3)c[s]2)=NNC1=O Chemical compound CC(C1)C(c2cc(-[n]3cncc3)c[s]2)=NNC1=O NPFVRBCDMFKOPY-UHFFFAOYSA-N 0.000 description 1
BEIZIEZPGSIQGR-UHFFFAOYSA-N CS(Nc1ccc(Oc(cc2)ccc2F)[s]1)(=O)=O Chemical compound CS(Nc1ccc(Oc(cc2)ccc2F)[s]1)(=O)=O BEIZIEZPGSIQGR-UHFFFAOYSA-N 0.000 description 1
YEEZWCHGZNKEEK-UHFFFAOYSA-N Cc(cccc1)c1S(NC(c1cc(OC)c(Cc(c2c3)c[n](C)c2ccc3NC(OC2CCCC2)=O)cc1)=O)(=O)=O Chemical compound Cc(cccc1)c1S(NC(c1cc(OC)c(Cc(c2c3)c[n](C)c2ccc3NC(OC2CCCC2)=O)cc1)=O)(=O)=O YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
ZGSYVUBKPBUTDW-UHFFFAOYSA-N NCc1ccc(C2(CC2)O)cc1 Chemical compound NCc1ccc(C2(CC2)O)cc1 ZGSYVUBKPBUTDW-UHFFFAOYSA-N 0.000 description 1
DABPGEIBZBRJFL-UHFFFAOYSA-N OC(c(cccn1)c1Oc1cc2n[s]nc2cc1)=O Chemical compound OC(c(cccn1)c1Oc1cc2n[s]nc2cc1)=O DABPGEIBZBRJFL-UHFFFAOYSA-N 0.000 description 1
0 [*+]c1ccc(*)[s]1 Chemical compound [*+]c1ccc(*)[s]1 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Oncology (AREA)
Virology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)

JP2001557868A 2000-01-31 2001-01-30 Ｐｄｅ４アイソザイムの選択的阻害薬として有用なニコチンアミドベンゾ縮合複素環誘導体 Expired - Fee Related JP3917863B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US17928400P	2000-01-31	2000-01-31
US60/179,284		2000-01-31
PCT/IB2001/000124 WO2001057036A1 (fr)	2000-01-31	2001-01-30	Derives benzocondenses heterocycliques de nicotinamide utiles comme inhibiteurs selectifs d'isozymes pde4

Publications (2)

Publication Number	Publication Date
JP2003522176A JP2003522176A (ja)	2003-07-22
JP3917863B2 true JP3917863B2 (ja)	2007-05-23

Family

ID=22655931

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2001557868A Expired - Fee Related JP3917863B2 (ja)	2000-01-31	2001-01-30	Ｐｄｅ４アイソザイムの選択的阻害薬として有用なニコチンアミドベンゾ縮合複素環誘導体

Country Status (41)

Country	Link
US (1)	US7354941B2 (fr)
EP (1)	EP1252158B1 (fr)
JP (1)	JP3917863B2 (fr)
KR (1)	KR20020072299A (fr)
CN (1)	CN1404481A (fr)
AP (1)	AP2002002589A0 (fr)
AR (1)	AR027337A1 (fr)
AT (1)	ATE293624T1 (fr)
AU (1)	AU2700201A (fr)
BG (1)	BG106852A (fr)
BR (1)	BR0107964A (fr)
CA (1)	CA2398182C (fr)
CO (1)	CO5261634A1 (fr)
CZ (1)	CZ20022410A3 (fr)
DE (1)	DE60110205T2 (fr)
EA (1)	EA004885B1 (fr)
EE (1)	EE200200425A (fr)
ES (1)	ES2238415T3 (fr)
GE (1)	GEP20043302B (fr)
GT (1)	GT200100022A (fr)
HN (1)	HN2001000019A (fr)
HU (1)	HUP0204262A2 (fr)
IL (1)	IL150641A0 (fr)
IS (1)	IS6421A (fr)
MA (1)	MA26870A1 (fr)
MX (1)	MXPA02007419A (fr)
NO (1)	NO20023613L (fr)
NZ (1)	NZ519547A (fr)
OA (1)	OA12169A (fr)
PA (1)	PA8511201A1 (fr)
PE (1)	PE20011058A1 (fr)
PL (1)	PL357995A1 (fr)
PT (1)	PT1252158E (fr)
PY (1)	PY0102109A (fr)
SK (1)	SK10142002A3 (fr)
SV (1)	SV2002000299A (fr)
TN (1)	TNSN01020A1 (fr)
TR (1)	TR200201880T2 (fr)
UY (1)	UY26569A1 (fr)
WO (1)	WO2001057036A1 (fr)
ZA (1)	ZA200206033B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7417038B1 (en) *	1998-10-15	2008-08-26	Imperial Innovations Limited	Methods of treating cachexia
CA2398514A1 (fr) *	2000-01-28	2001-08-02	Robert M. Abra	Liposomes contenant un compose piege place dans une solution sursaturee
EP1322614A2 (fr)	2000-09-18	2003-07-02	E. I. du Pont de Nemours and Company	Pyridinyl-amides et pyridinyl-imides utilis s comme fongicides
EE200300360A (et)	2001-01-31	2003-12-15	Pfizer Products Inc.	PDE4 isosüümide inhibiitoritena kasutatavad nikotiinamiidi biarüülderivaadid
ES2248231T3 (es) *	2001-01-31	2006-03-16	Pfizer Products Inc.	Derivados de eteres utiles como inhibidores de las isozimas pde4.
CN1489588A (zh)	2001-01-31	2004-04-14	�Ʒ�	用作pde4同功酶抑制剂的噻唑基,噁唑基,吡咯基,和咪唑基羧酸酰胺衍生物
US7250518B2 (en)	2001-01-31	2007-07-31	Pfizer Inc.	Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
GB0118373D0 (en) *	2001-07-27	2001-09-19	Glaxo Group Ltd	Novel therapeutic method
JP2005505570A (ja) *	2001-09-19	2005-02-24	アルタナ　ファルマ　アクチエンゲゼルシャフト	Ｐｄｅ阻害剤及びロイコトリエン受容体拮抗物質の複合薬
US20040242597A1 (en) *	2001-09-19	2004-12-02	Thomas Klein	Combination
IS7221A (is) *	2001-11-15	2004-04-15	Memory Pharmaceuticals Corporation	Hringlaga adenosínmónófosfat fosfódíesterasa 4D7 ísóform og aðferðir til notkunar þeirra
MXPA04007737A (es)	2002-02-11	2004-10-15	Pfizer	Derivados de nicotinamida utiles como inhibidores de fosfodesterasas 4.
US6756392B2 (en)	2002-02-11	2004-06-29	Pfizer Inc	Nicotinamide derivatives useful as PDE4 inhibitors
US6962940B2 (en)	2002-03-20	2005-11-08	Celgene Corporation	(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
WO2004047817A1 (fr) *	2002-11-27	2004-06-10	Altana Pharma Ag	Inhibiteurs de pde4 et pde3/4 que l'on utilise dans le traitement de la cachexie
AU2003300076C1 (en)	2002-12-30	2010-03-04	Angiotech International Ag	Drug delivery from rapid gelling polymer composition
JPWO2004087151A1 (ja) *	2003-03-31	2006-06-29	協和醗酵工業株式会社	医薬組成物
WO2004087150A1 (fr) *	2003-03-31	2004-10-14	Kyowa Hakko Kogyo Co. Ltd.	Composition pour medicaments
US20060199789A1 (en) *	2003-03-31	2006-09-07	Kyowa Hakko Kogyo Co., Ltd.	medical composition
EP1616024A1 (fr) *	2003-04-10	2006-01-18	F. Hoffmann-La Roche Ag	Utilisation de pde4d dans le criblage de medicaments contre l'atherosclerose
WO2004104022A2 (fr) *	2003-05-16	2004-12-02	The General Hospital Corporation	Compositions contenant un facteur chimio-tactique epithelial pathogene (eicosanoide et hepoxiline a3), leurs inhibiteurs et leurs procedes d'utilisation
GB0317516D0 (en)	2003-07-25	2003-08-27	Pfizer Ltd	Nicotinamide derivatives useful as PDE4 inhibitors
GB0317498D0 (en) *	2003-07-25	2003-08-27	Pfizer Ltd	Compounds
GB0317484D0 (en)	2003-07-25	2003-08-27	Pfizer Ltd	Nicotinamide derivatives useful as pde4 inhibitors
GB0317471D0 (en) *	2003-07-25	2003-08-27	Pfizer Ltd	Novel compounds
US7153870B2 (en)	2003-07-25	2006-12-26	Pfizer Inc.	Nicotinamide derivatives useful as PDE4 inhibitors
US7132435B2 (en)	2003-07-25	2006-11-07	Pfizer Inc.	Compounds
PE20060272A1 (es)	2004-05-24	2006-05-22	Glaxo Group Ltd	(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
EP1683795A1 (fr) *	2005-01-21	2006-07-26	Pfizer Limited	Formes crystallines de cis-5-fluoro-N-¬4-(2-hydroxy-4-methylbenzamido)cyclohexyl\|-2-(tetrahydrothiopyran-4-yloxy)nicotinamide
EP1844040A1 (fr) *	2005-01-21	2007-10-17	Pfizer Limited	Formes crystallines de cis-5-fluoro-n-[4-(2-hydroxy-4-methylbenzamido)cyclohexyl]-2-(tetrahydrothiopyran-4-yloxy)nicotinamide
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
GB0624282D0 (en) *	2006-12-05	2007-01-10	Cavalla David	Treatment of cachexia
WO2008079328A2 (fr) *	2006-12-22	2008-07-03	Creighton University	Acides gras oméga-5 utiles dans l'inhibition de la 5-lipoxygénase et dans le traitement du cancer
KR20100014565A (ko) *	2007-04-11	2010-02-10	알콘 리서치, 리미티드	알레르기성 비염 및 알레르기성 결막염을 치료하기 위한 ｔｎｆａ의 억제제 및 항히스타민의 용도
EP2196465A1 (fr)	2008-12-15	2010-06-16	Almirall, S.A.	Dérivés de (3-oxo)pyridazin-4-ylurée comme inhibiteurs de PDE4
EP2226323A1 (fr)	2009-02-27	2010-09-08	Almirall, S.A.	Nouveaux dérivés de tétrahydropyrazolo [3,4-c]isoquinoléine-5-amine
USRE46608E1 (en)	2009-09-01	2017-11-14	Catabasis Pharmaceuticals, Inc.	Fatty acid niacin conjugates and their uses
WO2011028689A1 (fr)	2009-09-01	2011-03-10	Catabasis Pharmaceuticals, Inc.	Conjugués acides gras niacine et leurs utilisations
EP2380890A1 (fr)	2010-04-23	2011-10-26	Almirall, S.A.	Nouveaux dérivés de 7,8-dihydro-1,6-naphthyridin-5(6h)-one comme PDE4 inhibiteurs
EP2386555A1 (fr) *	2010-05-13	2011-11-16	Almirall, S.A.	Nouveaux dérivés de cyclohéxylamine dotés d'activités agoniste bêta 2 adrénergique et antagoniste muscarinique m3
EP2394998A1 (fr)	2010-05-31	2011-12-14	Almirall, S.A.	Dérivés de 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl en tant qu'inhibiteurs de la PDE4
EP3270929B1 (fr) *	2015-03-17	2019-09-11	Lee, Sheau-Long	Utilisation de ginsenoside m1 pour la prévention ou le traitement de la silicose
US11116737B1 (en)	2020-04-10	2021-09-14	University Of Georgia Research Foundation, Inc.	Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4861891A (en) *	1988-08-31	1989-08-29	Pfizer Inc.	Antidepressant N-substituted nicotinamide compounds
TW429148B (en)	1995-10-27	2001-04-11	Pfizer	Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases
AU738037B2 (en)	1997-04-04	2001-09-06	Pfizer Products Inc.	Nicotinamide derivatives

2001
- 2001-01-30 CZ CZ20022410A patent/CZ20022410A3/cs unknown
- 2001-01-30 AP APAP/P/2002/002589A patent/AP2002002589A0/en unknown
- 2001-01-30 AT AT01901333T patent/ATE293624T1/de not_active IP Right Cessation
- 2001-01-30 TR TR2002/01880T patent/TR200201880T2/xx unknown
- 2001-01-30 OA OA1200200229A patent/OA12169A/en unknown
- 2001-01-30 EP EP01901333A patent/EP1252158B1/fr not_active Expired - Lifetime
- 2001-01-30 CA CA002398182A patent/CA2398182C/fr not_active Expired - Fee Related
- 2001-01-30 AU AU27002/01A patent/AU2700201A/en not_active Abandoned
- 2001-01-30 SK SK1014-2002A patent/SK10142002A3/sk unknown
- 2001-01-30 IL IL15064101A patent/IL150641A0/xx unknown
- 2001-01-30 PT PT01901333T patent/PT1252158E/pt unknown
- 2001-01-30 DE DE60110205T patent/DE60110205T2/de not_active Expired - Lifetime
- 2001-01-30 BR BR0107964-6A patent/BR0107964A/pt not_active Application Discontinuation
- 2001-01-30 CN CN01804340A patent/CN1404481A/zh active Pending
- 2001-01-30 JP JP2001557868A patent/JP3917863B2/ja not_active Expired - Fee Related
- 2001-01-30 NZ NZ519547A patent/NZ519547A/en unknown
- 2001-01-30 GE GE4906A patent/GEP20043302B/en unknown
- 2001-01-30 WO PCT/IB2001/000124 patent/WO2001057036A1/fr not_active Ceased
- 2001-01-30 MX MXPA02007419A patent/MXPA02007419A/es active IP Right Grant
- 2001-01-30 KR KR1020027009829A patent/KR20020072299A/ko not_active Ceased
- 2001-01-30 ES ES01901333T patent/ES2238415T3/es not_active Expired - Lifetime
- 2001-01-30 EA EA200200662A patent/EA004885B1/ru not_active IP Right Cessation
- 2001-01-30 EE EEP200200425A patent/EE200200425A/xx unknown
- 2001-01-30 PL PL01357995A patent/PL357995A1/xx not_active Application Discontinuation
- 2001-01-30 US US10/181,416 patent/US7354941B2/en not_active Expired - Fee Related
- 2001-01-30 HU HU0204262A patent/HUP0204262A2/hu unknown
- 2001-01-31 SV SV2001000299A patent/SV2002000299A/es not_active Application Discontinuation
- 2001-01-31 TN TNTNSN01020A patent/TNSN01020A1/fr unknown
- 2001-01-31 PY PY200100102109A patent/PY0102109A/es unknown
- 2001-01-31 UY UY26569A patent/UY26569A1/es not_active Application Discontinuation
- 2001-01-31 GT GT200100022A patent/GT200100022A/es unknown
- 2001-01-31 PE PE2001000110A patent/PE20011058A1/es not_active Application Discontinuation
- 2001-01-31 AR ARP010100436A patent/AR027337A1/es not_active Application Discontinuation
- 2001-01-31 CO CO01007017A patent/CO5261634A1/es not_active Application Discontinuation
- 2001-01-31 PA PA20018511201A patent/PA8511201A1/es unknown
- 2001-06-30 HN HN2001000019A patent/HN2001000019A/es unknown
2002
- 2002-06-13 IS IS6421A patent/IS6421A/is unknown
- 2002-06-20 BG BG106852A patent/BG106852A/bg unknown
- 2002-07-23 MA MA26739A patent/MA26870A1/fr unknown
- 2002-07-29 ZA ZA200206033A patent/ZA200206033B/en unknown
- 2002-07-30 NO NO20023613A patent/NO20023613L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
ZA200206033B (en)	2003-07-29
MA26870A1 (fr)	2004-12-20
CN1404481A (zh)	2003-03-19
MXPA02007419A (es)	2002-12-09
US20030186989A1 (en)	2003-10-02
CO5261634A1 (es)	2003-03-31
DE60110205D1 (de)	2005-05-25
WO2001057036A1 (fr)	2001-08-09
PL357995A1 (en)	2004-08-09
JP2003522176A (ja)	2003-07-22
EE200200425A (et)	2003-10-15
BG106852A (bg)	2003-02-28
ATE293624T1 (de)	2005-05-15
AU2700201A (en)	2001-08-14
TNSN01020A1 (fr)	2005-11-10
PT1252158E (pt)	2005-09-30
EA004885B1 (ru)	2004-08-26
GT200100022A (es)	2001-10-19
IS6421A (is)	2002-06-13
CA2398182C (fr)	2007-03-13
NZ519547A (en)	2004-03-26
PA8511201A1 (es)	2002-12-11
PE20011058A1 (es)	2001-10-23
IL150641A0 (en)	2003-02-12
BR0107964A (pt)	2002-10-29
HN2001000019A (es)	2001-09-06
OA12169A (en)	2006-05-08
TR200201880T2 (tr)	2002-11-21
EP1252158B1 (fr)	2005-04-20
SV2002000299A (es)	2002-07-03
DE60110205T2 (de)	2006-01-26
US7354941B2 (en)	2008-04-08
KR20020072299A (ko)	2002-09-14
NO20023613L (no)	2002-09-30
AP2002002589A0 (en)	2002-09-30
SK10142002A3 (sk)	2003-11-04
HUP0204262A2 (hu)	2003-04-28
UY26569A1 (es)	2001-08-27
GEP20043302B (en)	2004-02-10
NO20023613D0 (no)	2002-07-30
AR027337A1 (es)	2003-03-26
ES2238415T3 (es)	2005-09-01
PY0102109A (es)	2003-10-01
CA2398182A1 (fr)	2001-08-09
CZ20022410A3 (cs)	2003-08-13
EP1252158A1 (fr)	2002-10-30
EA200200662A1 (ru)	2002-12-26

Legal Events

Date	Code	Title	Description
2006-07-26	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060725
2006-07-28	A977	Report on retrieval	Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20060728
2006-10-17	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061016
2006-11-29	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061128
2006-12-02	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061201
2007-01-04	TRDD	Decision of grant or rejection written
2007-01-12	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070111
2007-02-15	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070209
2007-02-16	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150
2010-02-12	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20100216 Year of fee payment: 3
2010-02-16	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20110216 Year of fee payment: 4
2011-02-16	LAPS	Cancellation because of no payment of annual fees

Publication	Publication Date	Title
JP3917863B2 (ja)	2007-05-23	Ｐｄｅ４アイソザイムの選択的阻害薬として有用なニコチンアミドベンゾ縮合複素環誘導体
US6740655B2 (en)	2004-05-25	Pyrimidine carboxamides useful as inhibitors of PDE4 isozymes
US6953810B2 (en)	2005-10-11	Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes
US6894041B2 (en)	2005-05-17	Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes
US20020111495A1 (en)	2002-08-15	Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
JP2002284766A (ja)	2002-10-03	Ｐｄｅ４アイソザイムの阻害剤として活性なニコチンアミド酸類、アミド類およびそれらの模倣剤
US7250518B2 (en)	2007-07-31	Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
AU2002220966A1 (en)	2002-08-12	Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes